ANDA 202102, held by Alembic. Aripiprazole.
As of Nov 16, 2026, ANDA 202102 (Aripiprazole), held by Alembic, was first approved by FDA on Apr 28, 2015, with 11 approved supplements and 0 published complete response letters.
Aripiprazole Orally Disintegrating Tablets are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 28, 2015 | Original application | Approved |
| Aripiprazole10MG · tablet, orally disintegrating;oral | Aripiprazole | Rx |
| Aripiprazole15MG · tablet, orally disintegrating;oral | Aripiprazole | Rx |
| Jan 24, 2025 | Supplement 26Labeling · Standard review | Approved | None posted |
| Jan 13, 2025 | Supplement 25Labeling · Standard review | Approved | None posted |
| Feb 1, 2021 | Supplement 18Labeling · Standard review | Approved | None posted |
| Feb 5, 2020 | Supplement 17Labeling · Standard review | Approved | None posted |
| Feb 4, 2020 | Supplement 16Labeling · Standard review | Approved | None posted |
| Mar 29, 2017 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 29, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 29, 2017 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 29, 2017 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 29, 2017 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 18, 2016 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 28, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters